Disruption of mutually negative regulatory feedback loop between interferon-inducible p202 protein and the E2F family of transcription factors in lupus-prone mice

Journal of Immunology

Volumn 180, Issue 9, 2008, Pages 5927-5934

  Panchanathan, Ravichandran ^a,b   Xin, Hong ^b   Choubey, Divaker ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON INDUCIBLE P202; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F4; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; E2F1 PROTEIN, MOUSE; E2F2 PROTEIN, MOUSE; E2F4 PROTEIN, MOUSE; IFI202B PROTEIN, MOUSE; PHOSPHOPROTEIN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR E2F2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; FIBROBLAST; GENE MUTATION; GENE REPRESSION; GENETIC SUSCEPTIBILITY; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION INITIATION; ANIMAL; BIOSYNTHESIS; CELL STRAIN 3T3; DISEASE MODEL; EMBRYO (ANATOMY); GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; SPLEEN;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; DISEASE MODELS, ANIMAL; E2F1 TRANSCRIPTION FACTOR; E2F2 TRANSCRIPTION FACTOR; E2F4 TRANSCRIPTION FACTOR; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, KNOCKOUT; NIH 3T3 CELLS; PHOSPHOPROTEINS; RETINOBLASTOMA PROTEIN; SPLEEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 44449146089     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.9.5927     Document Type: Article

References (51)

1. Kotzin, B. L. 1996. Systemic lupus erythematosus. Cell 85: 303-306. (Pubitemid 26160701)
2. Tsokos, G. C., and G. M. Kammer. 2000. Molecular aberrations in human systemic lupus erythematosus. Mol. Med. Today 6: 418-424.
3. Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I interferon (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23: 307-336.
4. Jorgensen, T. N., M. R. Gubbels, and B. L. Kotzin. 2004. New insights into disease pathogenesis from mouse lupus genetics. Curr. Opin. Immunol. 16: 787-793. (Pubitemid 39423670)
5. Zhu, J., and C. Mohan. 2007. SLE 1, 2, 3. . . genetic dissection of lupus. Adv. Exp. Med. Biol. 601: 85-95.
6. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392. (Pubitemid 44354221)
7. Rozzo, S. J., J. D. Allard, D. Choubey, T. J. Vyse, S. Izui, G. Peltz, and B. L. Kotzin. 2001. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15: 435-443. (Pubitemid 32907390)
8. Haywood, M. E. K., S. J. Rose, S. Horswell, M. J. Lees, G. Fu, M. J. Walport, and B. J. Morley. 2006. Overlapping BXSB congenic intervals, in combination with microarray gene expression, reveal novel lupus candidate genes. Genes Immun. 7: 250-263.
9. Liu, J., G. Karypis, A. L. Vegoe, P. Ruiz, G. S. Gilkeson, and T. W. Behrens. 2006. Genomic view of systemic autoimmunity in MRL/lpr mice. Genes Immun. 7: 156-168.
10. Slansky, J. E., and P. J. Farnham. 1996. Introduction to the E2F family: protein structure and gene regulation. Curr. Top. Microbiol. Immunol. 208: 1-30.
11. Nevins, J. R. 1998. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 9: 585-593.
12. DeGregori, J. 2002. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochem. Biophys. Acta 1602: 131-150.
13. Iwase, S., Y. Furukawa, J. Kikuchi, M. Nagai, Y. Terui, M. Nakamura, and H. Yamada. 1997. Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells. J. Biol. Chem. 272: 12406-12414.
14. Thomas, N. S., A. R. Pizzey, S. Tiwari, C. D. Williams, and J. Yang. 1998. p130, p107, and pRb are differentially regulated in proliferating cells and during cell cycle arrest by α-interferon. J. Biol. Chem. 273: 23659-23667.
15. Johnson, D. G., K. Ohtani, and J. R. Nevins. 1994. Auto-regulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8: 1514-1525.
16. Yamasaki, L., T. Jacks, R. Bronson, E. Goillot, E. Harlow, and N. J. Dyson. 1996. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548.
17. Phillips, A. C., and K. H. Vousden. 2001. E2F-1 and apoptosis. Apoptosis 6: 173-182.
18. Choubey, D., J. Snoddy, V. Chaturvedi, E. Toniato, G. Opdenakker, A. Thakur, H. Samanta, D. A. Engel, and P. Lengyel. 1989. Interferons as gene activators. Indications for repeated gene duplication during the evolution of a cluster of interferon-activatable genes on murine chromosome 1. J. Biol. Chem. 264: 17182-17189.
19. Choubey, D., and P. Lengyel. 1993. Interferon action: cytoplasmic and nuclear localization of the interferon-inducible 52-kD protein that is encoded by the Ifi202 gene from the gene 200 cluster. J. Interferon Res. 13: 43-52.
20. Choubey, D. 2000. p202: an interferon-inducible negative regulator of cell growth. J. Biol. Regul. Homeostatic Agents 14: 187-192.
21. Choubey, D., and B. L. Kotzin. 2002. Interferon-inducible p202 in the susceptibility to systemic lupus. Front. Biosci. 7: e252-e262.
22. 1 mice. Genes Immun. 8: 653-662.
23. Lu, Q., N. Shen, X. M. Li, and S. L. Chen. 2007. Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun. 8: 590-603.
24. Santiago-Raber, M. L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788.
25. Geng, Y., S. D'Souza, H. Xin, S. Walter, and D. Choubey. 2000. p202 levels are negatively regulated by serum growth factors. Cell Growth Differ. 11: 475-483.
26. D'Souza, S., H. Xin, S. Walter, and D. Choubey. 2001. The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression. J. Biol. Chem. 276: 298-305.
27. Xin, H., Y. Geng, R. Pramanik, and D. Choubey. 2003. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival. J. Cell. Biochem. 88: 191-204.
28. Pramanik, R., T. N. Jorgensen, H. Xin, B. L. Kotzin, and D. Choubey. 2004. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J. Biol. Chem. 279: 16121-16127.
29. Murga, M., O. Fernandez,-Capetillo, S. J. Field, B. Moreno, L. R. Borlado, Y. Fujiwara, D. Balomenos, A. Vicario, A. C. Carrera, S. H. Orkin, et al. 2001. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 15: 959-970.
30. Zhu, J. W., S. J. Field, L. Gore, M. Thomson, H. Yang, Y. Fujiwara, R. D. Cardiff, M. Greenberg, S. H. Orkin, and J. DeGregori. 2001. E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol. Cell. Biol. 21: 8547-8564.
31. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
32. Classon, M., S. Salama, C. Gorka, R. Mulloy, P. Braun, and E. Harlow. 2000. Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc. Natl. Acad. Sci. USA 97: 10820-10825.
33. Tanaka, H., I. Matsumura, S. Ezoe, Y. Satoh, T. Sakamaki, C. Albanese, T. Machii, R. G. Pestell, and Y. Kanakura. 2002. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell. 9: 1017-1029.
34. Choubey, D., S. J. Li, B. Datta, J. U. Gutterman, and P. Lengyel. 1996. Inhibition of E2F-mediated transcription by p202. EMBO J. 15: 5688-5678.
35. Xin, H., R. Pramanik, and D. Choubey. 2003. Retinoblastoma (Rb) protein up-regulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth. Oncogene 22: 4775-4785.
36. Zhu, J. W., D. DeRyckere, F. X. Li, Y. Y. Wan, and J. DeGregori. 1999. A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth Differ. 10: 829-838.
37. Cress, W. D., D. G. Johnson, and J. R. Nevins. 1993. A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4. Mol. Cell. Biol. 13: 6314-6325.
38. Tao, Y., R. F. Kassatly, W. D. Cress, and J. M. Horowitz. 1997. Subunit composition determines E2F DNA-binding site specificity. Mol. Cell. Biol. 17: 6994-7007.
39. Choubey, D., and J. U. Gutterman. 1997. Inhibition of E2F-4/DP-1-stimulated transcription by p202. Oncogene 15: 291-301.
40. Brennam, P., J. W. Babbage, B. M. Burgering, B. Groner, K. Reif, and D. A. Cantrell. 1997. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7: 679-689.
41. Lam, E. W., J. Glassford, J. van der Sman, L. Banerji, A. R. Pizzey, N. Shaun, B. Thomas, and G. G. Klaus. 1999. Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. Eur. J. Immunol. 29: 3380-3389.
42. van der Sman, J., N. S. Thomas, and E. W. Lam. 1999. Modulation of E2F complexes during G0 to S phase transition in human primary B-lymphocytes. J. Biol. Chem. 274: 12009-12016.
43. Lam, E. W., M. S. Choi, J. van der Sman, S. A. Burbidge, and G. G. Klaus. 1998. Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. J. Biol. Chem. 273: 10051-10057.
44. Lissy, N. A., P. K. Davis, M. Irwin, W. G. Kaelin, and S. F. Dowdy. 2000. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407: 642-645.
45. Garcia, I., M. Murga, A. Vicario, S. J. Field, and A. M. Zubiaga. 2000. A role for E2F1 in the induction of apoptosis during thymic negative selection. Cell Growth Differ. 11: 91-98.
46. Cao, Q., Y. Xia, M. Azadniv, and I. N. Crispe. 2004. The E2F-1 transcription factor promotes caspase-8 and bid expression, and enhances Fas signaling in T cells. J. Immunol. 173: 1111-1117.
47. DeRyckere, D., and J. DeGregori. 2005. E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo. J. Immunol. 175: 647-655.
48. Urist, M., and C. Prives. 2002. p53 leans on its siblings. Cancer Cell. 1: 311-313.
49. Yan, D. H., A. Abramina, Z. Li, Y. Ding, Y. Wen, T. J. Liu, and K. Hunt. 2003. P202, an interferon-inducible protein, inhibits E2F1-mediated apoptosis in prostate cancer cells. Biochem. Biophys. Res. Commun. 303: 219-222.
50. Hershko, T., and D. Ginsberg. 2003. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279: 8627-8634.
51. Xin, H., S. D'Souza, T. N. Jorgensen, A. T. Vaughan, P. Lengyel, B. L. Kotzin, and D. Choubey. 2006. Increased expression of Ifi202, an IFN-activatable gene, in B6.Nba2 lupus susceptible mice inhibits p53-mediated apoptosis. J. Immunol. 176: 5863-5870.